Immune System News and Research

RSS

Men with asthma or eczema at lower risk of developing cancer

Men who had a history of asthma or eczema generally had a lower risk of developing cancer, according to a study carried out by researchers at INRS-Institut Armand-Frappier, the Research Centre of the Centre hospitalier de l'Université de Montréal, and McGill University. The findings, published in the Annals of Allergy, Asthma & Immunology, show that male eczema sufferers had a lower risk of lung cancer while those with a history of asthma had a similar effect in relation to stomach cancer.

21 Jul 2010

Natural, needle-free vaccination against malaria

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections. This discovery was made by the team headed by Dr. Steffen Borrmann from the Department of Infectious Diseases at Heidelberg University Hospital in cooperation with Dr. Kai Matuschewski of the Max Planck Institute for Infection Biology in Berlin. The scientists think that safe and affordable prophylaxis with antibiotics in residents of areas with high malaria transmission has the potential to be used as a natural "needle-free" vaccination against malaria.

21 Jul 2010

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

Neogen fiscal 2010 net income increases 26% to $17.5M

Neogen Corporation announced today that its net income for its 2010 fiscal year, which ended May 31, increased 26% from the previous year to $17,521,000. Net income in the fiscal year increased to $0.76 per share, compared to the prior year's $0.61, adjusted for a 3-for-2 stock split that was effective Dec. 15, 2009.

20 Jul 2010

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a Certificate of Product Registration from the FDA Philippines, certifying that its Resurgex Select product can now be marketed as a nutritional supplement for cancer patients and other immune-compromised individuals throughout the country.

20 Jul 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its second quarter 2010 results.

20 Jul 2010

Diffused ultraviolet radiation penetrates beach umbrellas

A team of researchers from the University of Valencia (UV) has proven that 34% of ultraviolet radiation filters through under beach umbrellas. According to what is published in the journal Photochemistry and Photobiology, umbrellas intercept the full direct flow that comes from the Sun, but not the diffused radiation that penetrates through from the sides.

20 Jul 2010

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

The flood of scientific evidence on omega-3 eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) has significantly buoyed the credibility of polyunsaturated fatty acids (PUFAs) as vital functional ingredients. Heightened consumer awareness has had a telling effect on the healthy growth charts of the marine and algae oil omega-3 ingredients market.

20 Jul 2010

Scientists develop new way to increase effectiveness of antiviral drugs

Scientists have developed a new way to target viruses which could increase the effectiveness of antiviral drugs.Instead of attacking the virus itself, the method developed at the University of Edinburgh alters the conditions which viruses need to survive and multiply.

20 Jul 2010

Researchers identify a substance that protects farm children from allergies, allergic asthma

Researchers from Bochum have isolated the substance in cowshed dust that possibly protects farm children from developing allergies and allergic asthma, namely the plant sugar molecule arabinogalactan. If high concentrations thereof are inhaled during the first year of life it inhibits the immune system from excessive defense reactions.

20 Jul 2010

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.

20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

WHO advises earlier treatment for people with HIV

An estimated 5.2 million people were receiving life-saving HIV treatment at the end of 2009, according to the latest update from the WHO. WHO estimates that 1.2 million people started treatment in 2009, bringing the total number of people receiving treatment to 5.2 million, compared to 4 million at the end of 2008.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.

19 Jul 2010

Study evaluates immunization benefits of dissolving microneedles

A new vaccine-delivery patch based on hundreds of microscopic needles that dissolve into the skin could allow persons without medical training to painlessly administer vaccines - while providing improved immunization against diseases such as influenza.

19 Jul 2010

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Scientists from the Department of Molecular Immunology, Institute of Biology III, Faculty of Biology and the Centre for Biological Signalling Studies, BIOSS have discovered a new mechanism that drives the development of B-lymphocytes in our bone marrow. B-lymphocytes are an important part of our immune system. Upon their activation they produce the antibodies protecting us from infections.

17 Jul 2010

Study examines HIV-positive patients' death risk at CD4 counts above 350

"Having HIV appears to be associated with a greater risk of death, even when the immune system is relatively robust and patients have not started treatment," according to a study published Friday in the Lancet, MedPage Today reports (Smith, 7/15).

17 Jul 2010

Immune System News and Research

Men with asthma or eczema at lower risk of developing cancer

Natural, needle-free vaccination against malaria

GCSF administration can reduce side effects of cancer neurobastoma in children

Neogen fiscal 2010 net income increases 26% to $17.5M

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Diffused ultraviolet radiation penetrates beach umbrellas

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

Scientists develop new way to increase effectiveness of antiviral drugs

Researchers identify a substance that protects farm children from allergies, allergic asthma

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Scientists find major shortcomings in assessing CVD risk in HIV patients

WHO advises earlier treatment for people with HIV

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

Study evaluates immunization benefits of dissolving microneedles

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Study examines HIV-positive patients' death risk at CD4 counts above 350

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News